|Description||EBPC is a potent and selective aldose reductase inhibitor. It is used to improve the cytotoxicity of anticancer reagents such as cisplatin and doxorubicin in HeLa cervical carcinoma cells via an increase in ERK activity.|
|Brife Description||aldose reductase inhibitor|
|Purity||≥99% by HPLC|
|Appearance||Pale Pink Solid|
|Synonyms||Ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate; 1-Benzyl-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid ethyl ester; MFCD00179167; 1-benzyl-4-[ethoxy(hydroxy)methylidene]pyrrolidine-2,3-dione|
Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM.
FR-62765, a derivative of WF-3681, is a novel aldose reductase inhibitor. It might be a useful drug for diabetic neuropathy.
Tolrestat is an orally active and potent aldose reductase inhibitor with IC50 value of 35 nM. It was approved for the control of certain diabetic complications....
Zenarestat is an aldose reductase inhibitor. It was investigated as a treatment of diabetic neuropathy and cataract. It was developed by Fujisawa Pharmaceutical...
Alrestatin sodium is a specific inhibitor of aldose reductase (IC50 = 148 μM).
Raniestat, a highly potent aldose reductase inhibitor currently under phase III clinical trials in the US and Canada, is used to treat diabetic neuropathies.
Aldose reductase-IN-1, an aldose reductase inhibitor, could have potential biological usage in the study of breast cancer. IC50: 28.9 pM.
Isoliquiritigenin, an anti-tumor flavonoid from the root of Glycyrrhiza glabra, inhibiting aldose reductase with an IC50 of 320 nM.